<SEC-DOCUMENT>0001213900-18-002270.txt : 20180226
<SEC-HEADER>0001213900-18-002270.hdr.sgml : 20180226
<ACCEPTANCE-DATETIME>20180226090812
ACCESSION NUMBER:		0001213900-18-002270
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20180226
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180226
DATE AS OF CHANGE:		20180226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actinium Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001388320
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880378336
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36374
		FILM NUMBER:		18638800

	BUSINESS ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016
		BUSINESS PHONE:		646-677-3875

	MAIL ADDRESS:	
		STREET 1:		275 MADISON AVENUE, 7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Cactus Ventures, Inc.
		DATE OF NAME CHANGE:	20070130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k022618_actiniumpharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pursuant
to Section 13 or 15(d) of the</B><BR>
<B>Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): February 26, 2018</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52446</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>74-2963609</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction<BR>
    of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>275
    Madison Avenue, 7th Floor</B><BR>
    <B>New York, NY</B></FONT></TD>
    <TD STYLE="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10016</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&rsquo;s
telephone number, including area code: <B>(646) 677-3870</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 100%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>N/A</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
    name or former address, if changed since last report)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5.03 Amendments to Articles of&nbsp;Incorporation or Bylaws; Change in Fiscal Year.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 47.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2018, Actinium Pharmaceuticals, Inc. (&ldquo;Actinium&rdquo;) filed a Certificate of Amendment to its Certificate
of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares
of Actinium&rsquo;s common stock from 200,000,000 to 400,000,000 shares (the &ldquo;<U>Charter Amendment</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously disclosed in Item 5.07 of the Current Report on Form 8-K filed with the Securities and Exchange Commission on December
21, 2017, the Charter Amendment was approved by Actinium&rsquo;s stockholders at the 2017 annual meeting of stockholders held
on December 20, 2017. The foregoing description of the Charter Amendment does not purport to be complete and is&nbsp;qualified
in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 to this Current
Report on Form 8-K and incorporated in this Item 5.03 by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01 Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2018, Actinium issued a press release (the &ldquo;Press Release&rdquo;) announcing an amendment to the pricing
terms of its previously announced rights offering. Under the amended rights offering terms, Actinium would distribute
non-transferable subscription rights to purchase 50,000,000 units at a subscription price per unit of $0.50, to its
stockholders and certain participating warrant holders on the record date. The subscription rights will be exercisable for up
to an aggregate of $25.0 million of units, subject to increase at the discretion of the Company, with aggregate participation
to be allocated among holders on a pro rata basis if in excess of that threshold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
unit will consist of one share of common stock, 0.25 series A warrants and 0.75 series B warrants. The series A warrants will
have a term of 12 months from the date of issuance and will have a reduced exercise price of $0.60, under the amended rights
offering terms. The series B warrants will have a term of 30 months from the date of issuance and will have a
reduced exercise price of $0.70, under the amended rights offering terms. The redemption price threshold for the series A
warrants is $1.20 per share, and the redemption price threshold for the series B warrants is $2.10 per share. <FONT STYLE="color: Black">Under
the amended rights offering terms, the redemption price thresholds for the Series A warrants and the Series B warrants
were also reduced to $1.20 per share of common stock, for the series A warrants, and $2.10 per share of common stock, for
the series B warrants.&nbsp; Actinium may redeem the series A warrants and the series B warrants, as applicable, at a
redemption price of $0.001 per warrant, if its common stock closes above such threshold prices for ten consecutive trading
days.</FONT></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Holders who fully exercise their basic subscription
rights will be entitled, if available, to subscribe for an additional amount of units that are not purchased by other
holders, on a pro rata basis and subject to the $25.0 million aggregate offering threshold and other ownership limitations.
The subscription rights are non-transferrable and may only be exercised during the anticipated subscription period of
Thursday, February 15, 2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Form
of Non-Transferable Subscription Rights Certificate (the &ldquo;Rights Certificate&rdquo;) and the form of Beneficial Owner
Election Form (the &ldquo;Election Form&rdquo;), as revised under the amended rights offering terms, are also attached hereto
as Exhibits 4.1 and 99.2, respectively. These exhibits reflect the amended rights offering terms described above. The foregoing
descriptions of the Press Release, the Rights Certificate and the Election Form do not purport to be complete and
each are&nbsp;qualified in their entirety by reference to the full text of the Press Release, the Rights Certificate and the
Election Form, copies of which are filed as Exhibits 99.1, 4.1 and 99.3, respectively, to this Current Report on Form 8-K
and are incorporated in this Item 8.01 by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Financial Statements and Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>No.</B></FONT></TD>
    <TD STYLE="width: 0.1in; text-align: center; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="f8k022618ex3-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised
    Certificate of Amendment to Actinium&rsquo;s Certificate of Incorporation, as amended, filed with the Secretary of State of
    the State of Delaware on February 26, 2018</FONT></A></TD></TR>

<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="f8k022618ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised
    Form of Non-Transferable Subscription Rights Certificate.</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="f8k022618ex99-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release of Actinium Pharmaceuticals, Inc., dated February 26, 2018.</FONT></A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><A HREF="f8k022618ex99-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revised
    Form of Beneficial Owner Election Form.</FONT></A></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    February 26, 2018</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACTINIUM
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sandesh Seth</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh
    Seth</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CEO
    &amp; Chairman</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">3</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>f8k022618ex3-1_actinium.htm
<DESCRIPTION>CERTIFICATE OF AMENDMENT TO ACTINIUM'S CERTIFICATE OF INCORPORATION, AS AMENDED, FILED WITH THE SECRETARY OF STATE OF THE STATE OF DELAWARE ON FEBRUARY 26, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: right; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><B>Exhibit 3.1</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><B>STATE OF DELAWARE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
CERTIFICATE OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST:
</B>That at a meeting of the Board of Directors of <U>Actinium Pharmaceuticals, Inc.</U> resolutions were duly adopted setting
forth a proposed amendment of the Certificate of Incorporation of said corporation, declaring said amendment to be advisable
and calling a meeting of the stockholders of said corporation for consideration thereof. The resolution setting forth the proposed
amendment is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RESOLVED,
</B>that the Certificate of Incorporation of this corporation be amended by changing the Article thereof numbered &ldquo;<U>FOURTH</U>&rdquo;
so that, as amended, said Article shall be and read as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amount of the total stock this Corporation is authorized to issue is 450,000,000 shares with a par value of $0.001 per
share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Common Stock. The aggregate number of shares of Common Stock which the Corporation shall have the authority to issue is 400,000,000
shares at a par value of $0.001 per share. (see attached)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND:
</B>That thereafter, pursuant to resolution of its Board of Directors, a special meeting of the stockholders of said corporation
was duly called and held upon notice in accordance with Section 222 of the General Corporation Law of the State of Delaware at
which meeting the necessary number of shares as required by statute were voted in favor of the amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD:
</B>That said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the
State of Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF,</B> said corporation has caused this certificate to be signed this <U>26th</U> day of <U>February</U>, &#9;<U>2018</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0; width: 5%">By:</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0; width: 35%; border-bottom: Black 1.5pt solid">/s/ Sandesh Seth</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0.5in; padding-top: 0; text-indent: 0">Authorized Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0">Title:</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0; border-bottom: Black 1.5pt solid">Chairman of the Board &amp; CEO</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0">Name:</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0; border-bottom: Black 1.5pt solid">Sandesh Seth</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0.5in; padding-top: 0; text-indent: 0">Print or Type</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Preferred Stock. The aggregate number of shares of Preferred Stock which the Corporation shall have the authority to issue
is 50,000,000 shares, par value $0.001, which may be issued in series, with such designations, preferences, stated values,
rights, qualifications or limitations as determined solely by the Board of Directors of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Preemptive Rights. No stockholder of the Corporation shall have any preemptive right to subscribe to an additional issue of
stock or to any security convertible into such stock of the Corporation.</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>f8k022618ex4-1_actinium.htm
<DESCRIPTION>FORM OF NON-TRANSFERABLE SUBSCRIPTION RIGHTS CERTIFICATE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF NON-TRANSFERABLE SUBSCRIPTION
RIGHTS CERTIFICATE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 53%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIGHTS CERTIFICATE # [______]</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%; text-align: right; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NUMBER OF RIGHTS: [______]</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">THE TERMS AND CONDITIONS OF THE
RIGHTS OFFERING ARE SET FORTH IN THE COMPANY'S PROSPECTUS SUPPLEMENT DATED FEBRUARY 15, 2018, AS AMENDED FEBRUARY 26, 2018, AS
IT MAY BE FURTHER AMENDED FROM TIME TO TIME (THE &ldquo;<B>PROSPECTUS SUPPLEMENT</B>&rdquo;), AND ARE INCORPORATED HEREIN BY
REFERENCE. COPIES OF THE PROSPECTUS SUPPLEMENT ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC.,
THE INFORMATION AGENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Incorporated under the laws of the State
of Delaware)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SUBSCRIPTION RIGHTS CERTIFICATE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Evidencing non-transferable Subscription
Rights, each to purchase Units of Actinium Pharmaceuticals, Inc.,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">each Unit consisting of one share of Common
Stock, 0.25 Series A Warrants and 0.75 Series B Warrants</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subscription Price: $0.50 per Unit</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">THE SUBSCRIPTION RIGHTS WILL EXPIRE IF NOT
EXERCISED ON OR BEFORE 5:00 P.M., EASTERN TIME,<BR>
ON MARCH 2, 2018,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SUBJECT TO EXTENSION OR EARLIER TERMINATION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">THIS CERTIFIES THAT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">the registered owner whose name is inscribed
hereon is the owner of the number of subscription rights (&ldquo;<B>Subscription Rights</B>&rdquo;) set forth above. Each Subscription
Right entitles the holder thereof to subscribe for and purchase (the &ldquo;<B>Basic Subscription Right</B>&rdquo;) one Unit of
Actinium Pharmaceuticals, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), at a subscription price of $0.50 per Unit
(the &ldquo;<B>Subscription Price</B>&rdquo;), pursuant to a rights offering (the &ldquo;<B>Rights Offering</B>&rdquo;), on the
terms and subject to the conditions set forth in the Prospectus Supplement and the &ldquo;Instructions as to Use of Actinium Pharmaceuticals,
Inc. Subscription Rights Certificates&rdquo; accompanying this Subscription Rights Certificate. Each Unit consists of one share
of Common Stock, par value of $0.001, 0.25 Series A Warrants, and 0.75 Series B Warrants. Each WHOLE Series A Warrant and each
whole Series B Warrant will be exercisable for one share of our common stock, par value of $0.001. Holders who fully exercise their
Basic Subscription Rights are entitled to subscribe for additional Units that remain unsubscribed for as a result of any unexercised
Basic Subscription Rights pursuant to the terms and conditions of the Rights Offering, subject to proration and stock ownership
limitations, as described in the Prospectus Supplement (the &ldquo;<B>Over-subscription Privilege</B>&rdquo;). The Subscription
Rights represented by this Subscription Rights Certificate may be exercised by completing the appropriate forms on the reverse
side hereof and by returning the full payment of the subscription price for each Unit. If the subscriber attempts to exercise its
Over-subscription Privilege and the Company is unable to issue the subscriber the full amount of Units requested, the Subscription
Agent will return to the subscriber any excess funds submitted as soon as practicable, without interest or deduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This Subscription Rights Certificate is
not valid unless countersigned by Broadridge Corporate Issuer Solutions, Inc., the Subscription Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">WITNESS the seal of Actinium Pharmaceuticals,
Inc. and the signatures of its duly authorized officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dated: February 26, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sandesh Seth, Chairman &amp; Chief Executive Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">COUNTERSIGNED AND REGISTERED:</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 52%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 9%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 36%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadridge Corporate Issuer Solutions, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>FORM ELECTION TO PURCHASE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLEASE PRINT ALL INFORMATION CLEARLY
AND LEGIBLY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The registered holder of this Subscription
Rights Certificate is entitled to exercise the number of Subscription Rights shown in the upper right hand corner of the Subscription
Rights Certificate and may subscribe for additional Units upon the terms and conditions specified in the Prospectus. The undersigned
hereby represents, in connection with this election, that the undersigned has not since the Record Date entered into any short
sale or similar transaction with respect to the common stock of Actinium Pharmaceuticals, Inc. The undersigned hereby notifies
the Subscription Agent of its irrevocable election to subscribe for Units in the following amounts. To subscribe for Units pursuant
to your Basic Subscription Right, please complete lines (a) and (c) below. To subscribe for additional Units pursuant to your Over-subscription
Privilege, please also complete line (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)</B></FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXERCISE OF BASIC SUBSCRIPTION RIGHT:</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD NOWRAP STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic Subscription Right:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.50</FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number&nbsp;of&nbsp;Units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Subscription price&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Payment&nbsp;enclosed&nbsp;&nbsp;</FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)</B></FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXERCISE OF OVER-SUBSCRIPTION PRIVILEGE:&nbsp;</B>If you have exercised your Basic Subscription Right in full, you may subscribe for additional Units pursuant to your Over-subscription Privilege</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD NOWRAP STYLE="width: 34%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-Subscription Privilege:</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$0.50</FONT></TD>
    <TD STYLE="width: 24%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">=</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 6%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number&nbsp;of&nbsp;Units</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Subscription price&nbsp;&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;Payment&nbsp;enclosed</FONT></TD>
    <TD NOWRAP>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(c)</B></FONT></TD>
    <TD STYLE="width: 97%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TOTAL AMOUNT OF PAYMENT ENCLOSED $<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(d)</B></FONT></TD>
    <TD STYLE="width: 97%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IF YOU SPOKE WITH A BROKER WHO SOLICITED SUCH EXERCISE, PLEASE INDICATE THE NAME AND CONTACT INFORMATION OF THE PERSON YOU SPOKE WITH:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>METHOD OF PAYMENT (CHECK ONE)</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 96%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTIFIED CHECK DRAWN ON A U.S. BANK, payable to &ldquo;Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent for Actinium Pharmaceuticals, Inc.&rdquo;</FONT></TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Wire transfer of immediately available
        funds directly to the account maintained by Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent, for purposes of
        accepting subscriptions in this Rights Offering at</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">ABA/Routing number: 121000248</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">Bank: Wells Fargo</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">420 Montgomery Street</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">San Francisco, CA 94104 United States</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">Beneficiary Account Name: Broadridge Corporate Issuer
        Solutions</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">Account Number: 4124218686</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">FFC: Actinium Pharmaceuticals, Inc.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt">Account Number: 4399752260</P></TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. POSTAL MONEY ORDER, payable to &ldquo;Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent for Actinium Pharmaceuticals, Inc.&rdquo;</FONT></TD></TR>
<TR>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNCERTIFIED PERSONAL CHECK, payable to &ldquo;Broadridge Corporate Issuer Solutions, Inc., as Subscription Agent for Actinium Pharmaceuticals, Inc.&rdquo; (which must clear before the Expiration Date to be considered a valid form of payment; please see Prospectus Supplement and Instructions)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">I acknowledge receipt of the Prospectus
Supplement in connection with the Rights Offering and agree to its terms. I agree to cooperate with the Company and provide to
the Company any and all information requested by the Company in connection with the exercise of the Subscription Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 40%; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 18%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 40%; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature(s) of Subscriber(s)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Signature(s) of Subscriber(s)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Address:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>IMPORTANT: THE SIGNATURE(S) MUST CORRESPOND
IN EVERY PARTICULAR, WITHOUT ALTERATION, WITH THE NAME(S) AS PRINTED ON THE FRONT OF THIS RIGHTS CERTIFICATE.&nbsp;</B>If signature
is by trustee(s), executor(s), administrator(s), guardian(s), attorney(s)-in-fact, officer(s) of a corporation or another acting
in a fiduciary or representative capacity, please print name and title of authorized signer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">FOR INSTRUCTIONS ON THE USE OF ACTINIUM
PHARMACEUTICALS, INC. SUBSCRIPTION RIGHTS CERTIFICATES, CONSULT BROADRIDGE CORPORATE ISSUER SOLUTIONS, INC., THE INFORMATION AGENT,
AT (855) 793-5068 (TOLL FREE).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>f8k022618ex99-1_actinium.htm
<DESCRIPTION>PRESS RELEASE OF ACTINIUM PHARMACEUTICALS, INC., DATED FEBRUARY 26, 2018
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Actinium
Pharmaceuticals Reiterates Previously Announced</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Expiration
Date of March 2, 2018 at 5:00 PM ET and Amendment to</I></B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Pricing
Terms of its Rights Offering</I></B></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">-</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Pricing
                                         of the units has been amended to $0.50 per unit with corresponding amendments to the
                                         warrant exercise prices</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">-</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Timing
                                         of the offering is expected to be unchanged and the subscription period is expected to end
                                         on March 2, 2018 at 5:00 PM ET</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">-</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Record
                                         holders will receive their subscription rights certificate by mail and must return the
                                         subscription card appended thereto to Broadridge Corporate Issuer Solutions, Inc. by
                                         5:00 PM ET on Friday, March 2, 2018</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">-</FONT></TD><TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Beneficial
                                         owners will receive their beneficial owner election card via their broker, dealer, bank
                                         or other nominee, along with instructions on how to exercise their rights, and may have
                                         to do so by an earlier deadline that is determined by their broker, dealer, bank or other
                                         nominee</FONT></TD></TR></TABLE>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEW
YORK, NY &ndash; February 26, 2018 &ndash; Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (&ldquo;Actinium&rdquo; or &ldquo;the
Company&rdquo;)</B>, announced today that it has amended the pricing terms of its previously announced rights offering. Under the
amended rights offering terms, Actinium would distribute non-transferable subscription rights to purchase 50,000,000 units at
a subscription price per unit of $0.50, to its stockholders and certain participating warrant holders on the record date. The
subscription rights will be exercisable for up to an aggregate of $25.0 million of units, subject to increase at the discretion
of the Company, with aggregate participation to be allocated among holders on a pro rata basis if in excess of that threshold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
unit will consist of one share of common stock, 0.25 series A warrants and 0.75 series B warrants. The series A warrants
will have a term of 12 months from the date of issuance and will have a reduced exercise price of $0.60, under the amended
rights offering terms. The series B warrants will have a term of 30 months from the date of issuance and will have a reduced
exercise price of $0.70, under the amended rights offering terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
who fully exercise their basic subscription rights will be entitled, if available, to subscribe for an additional amount of units
that are not purchased by other holders, on a pro rata basis and subject to the $25.0 million aggregate offering threshold and
other ownership limitations. The subscription rights are non-transferrable and may only be exercised during the anticipated subscription
period of Thursday, February 15, 2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of record, participating warrant holders of record and other beneficial owners of common stock as of the rights offering record
date of February 14, 2018 will be receiving notification and subscription documentation. Stockholders of record and participating
warrant holders will receive their subscription rights certificate by mail, and those wishing to participate in the rights offering
must complete their subscription card and return it to Broadridge along with payment. The subscription rights certificate can
also be accessed via Actinium&rsquo;s Form 8-K, which was filed on February 26, 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><A HREF="f8k022618ex4-1_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
4.1 to the accompanying Form 8-K</FONT></A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
record holders of rights that wish to participate in the rights offering must deliver a properly completed and signed subscription
card, in the form attached to the subscription rights certificate, together with payment of the subscription price for both basic
subscription rights and any over subscription privilege election for delivery no later than 5:00 PM Eastern Time on March 2, 2018
to the Subscription Agent:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
mail:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadridge
Corporate Issuer Solutions, Inc.<BR>
Attn: BCIS Re-Organization Dept.<BR>
P.O. Box 1317<BR>
Brentwood, New York 11717-0693</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(855)
793-5068 (toll free)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
hand or overnight courier:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadridge
Corporate Issuer Solutions, Inc.<BR>
Attn: BCIS IWS<BR>
51 Mercedes Way<BR>
Edgewood, New York 11717</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(855)
793-5068 (toll free)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
owners will receive their beneficial owner election card via their broker, dealer, bank or other nominee along with instructions.
If exercising subscription rights through a broker, dealer, bank or other nominee, rights holders should promptly contact their
nominee and submit subscription documents and payment for the units subscribed for in accordance with the instructions and within
the time period provided by such nominee. The broker, dealer, bank or other nominee may establish a deadline before March 2, 2018,
by which instructions to exercise subscription rights, along with the required subscription payment, must be received. The beneficial
owner election card can also be accessed via Actinium&rsquo;s Form 8-K, which was filed on February 26, 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><A HREF="f8k022618ex99-2_actinium.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
99.2 to the accompanying Form 8-K</FONT></A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
questions about the rights offering or requests for copies of the prospectus, please contact Broadridge Corporate Issuer Solutions,
Inc., the Information Agent for the rights offering, at (855) 793-5068 (TOLL FREE) or Maxim Group LLC, at (212) 895-3745 or <U>syndicate@maximgrp.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
questions for the Company, information or requests for materials, please contact:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Steve
O&rsquo;Loughlin</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Principal
Financial Officer</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Actinium
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Email:
<U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">Phone:
(646) 677-3875</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
a result of the foregoing revisions to the pricing terms of the rights offering, any holders of subscription rights who have already
exercised their subscription rights at the original subscription price of $0.70 per unit, or who submit election forms referencing
the original subscription price of $0.70 per unit, will be considered to have exercised their subscription rights at the revised
subscription price of $0.50 per unit and will receive the appropriate number of shares of common stock, series A warrants and
series B warrants as if such holder had subscribed at the revised subscription price of $0.50 per unit.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
intends to use the proceeds from the rights offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product
candidate Iomab-B, generate topline results and support the filing of a BLA application with the U.S. Food and Drug Administration
(FDA), all of which are anticipated to cost an aggregate of approximately $12 to $15 million. Iomab-B is a first in class therapy
being developed for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed
or refractory acute myeloid leukemia (AML) age 55 and older. The SIERRA trial is randomized and controlled 150-patient trial that
is currently active at 15 clinical trial sites in the United States. Actinium&rsquo;s CD33 program is currently comprised of an
ongoing Phase 2 clinical trial for Actimab-A and Phase 1 trial for Actimab-M which are expected to generate top line results in
2018 as well as a planned Phase 2 trial for Actimab-MDS. The Company intends to partner the CD33 program and believes that data
from these trials as well as the Actimab-MDS trial will support this strategy and establish its program as the industry leader.
Consequently, the Company may elect to use any additional proceeds above $15 million to fund proof-of-concept of its planned Phase
2 Actimab-MDS trial from the CD33 Program, if appropriate, as it believes this can further support its partnering strategy for
the CD33 program. Actinium will also use the proceeds to support its AWE Technology Platform, research and development and general
working capital needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be
any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
registration statement on Form S-3 relating to these securities has been filed by the Company with the SEC. The rights offering
will only be made by means of a prospectus. A preliminary prospectus relating to and describing the proposed terms of the rights
offering has been filed with the SEC as a part of the&nbsp;registration&nbsp;statement and is available on the SEC&rsquo;s web
site.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Actinium Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actinium
Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies
for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting
and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access
to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC&rsquo;s
or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.
Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the
isotope Actinium-225 (Ac<SUP>225</SUP>) that emits alpha particles. We are currently conducting clinical trials for our four product
candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing
our proprietary AWE Technology Platform. Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson
Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting
a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for
patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially
curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as
certain blood disorders. Iomab-B has been tested in several of these other cancers with over five hundred patients treated in
several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend
to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug.
We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab
labeled with the alpha-particle emitter actinium-225. Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase
2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction
chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 targeting ARC, is being
studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS,
our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have
a p53 genetic mutation. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial
Sloan Kettering Cancer Center, is focused on leveraging Actinium&rsquo;s know how and intellectual property to create additional
ARC drug candidates by labeling Ac<SUP>225</SUP> to targeting moieties that we will either progress in clinical trials ourselves
or out-license.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
information is available at <U>www.actiniumpharma.com</U> and our Twitter feed @ActiniumPharma, <U>www.twitter.com/actiniumpharma</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements for Actinium Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain projections or other &ldquo;forward-looking statements&rdquo; within the meaning of the &ldquo;safe-harbor&rdquo;
provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance
of the Company which the Company undertakes no obligation to update. These statements are based on management&rsquo;s current
expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated
or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final
results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental
agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium&rsquo;s products
and services, performance of clinical research organizations and other risks detailed from time to time in Actinium&rsquo;s filings
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.5pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actinium
Pharmaceuticals, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve
O&rsquo;Loughlin</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice President, Finance and Corporate Development</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>soloughlin@actiniumpharma.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marek
Ciszewski, J.D.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">949.574.3860</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATNM@liolios.com</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>f8k022618ex99-2_actinium.htm
<DESCRIPTION>FORM OF BENEFICIAL OWNER ELECTION FORM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BENEFICIAL OWNER ELECTION FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ACTINIUM PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The undersigned acknowledge(s) receipt
of your letter and the enclosed materials referred to therein relating to the rights offering (the &ldquo;Rights Offering&rdquo;)
by Actinium Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;), of non-transferable subscription rights
(the &ldquo;Subscription Rights&rdquo;) to purchase units (the &ldquo;Units&rdquo;), each such Unit comprised of a share of the
Company's Common Stock, $0.001 par value (&ldquo;Common Stock&rdquo;), 0.25 Series A Warrants, and 0.75 Series B Warrants. Each
Series A Warrant and Series B Warrant will be exercisable for one share of the Company's Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This will instruct you whether to
exercise Subscription Rights to purchase Units distributed with respect to the shares of Common Stock or participating
warrants held by you for the account of the undersigned, pursuant to the terms and subject to the conditions set forth in the
prospectus supplement, dated February 15, 2018, as amended February 26, 2108, as it may be further amended from time to time
(the &ldquo;Prospectus Supplement&rdquo;). (Check the applicable boxes and provide all required information.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Please DO NOT EXERCISE SUBSCRIPTION RIGHTS for Units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 95%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Please EXERCISE SUBSCRIPTION RIGHTS for Units as set forth below:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 54%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 10%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>No. of Units</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: right">&nbsp;</TD>
    <TD NOWRAP STYLE="vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Per Unit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Subscription</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>Price</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 13%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Payment</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Basic Subscription Right</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">[____]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$0.50</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$[____]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Over-Subscription Privilege</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">[____]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP><FONT STYLE="font-size: 10pt">X</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$0.50</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">=</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$[____]</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Total Payment Required</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">$[____]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">If you spoke with a broker who solicited
such exercise, please indicate the name and contact information of the person you spoke with:&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Payment in the following amount is enclosed $______ (must match Total Payment Required above)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 95%"><FONT STYLE="font-size: 10pt">Please deduct payment from the following account maintained by you as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">Type of Account:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">Account No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">Amount to be deducted: $</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 166.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0pt; margin-bottom: 0pt; text-align: left">I
(we) on my (our) own behalf, or on behalf of any person(s) on whose behalf, or under whose directions, I am (we are) signing this
form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 48px">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">irrevocably elect to purchase the number of Units indicated above upon the terms and conditions specified in the Prospectus Supplement; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 48px">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 48px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">agree that if I (we) fail to pay for the shares I (we) have elected to purchase, the exercise will be invalid.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Telephone:</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #$ RH# 2(  A$! Q$!_\0
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MN*_*WP%XH\4_#'Q5;^(/"XN$NT.V6W\IS#=1]XY% Y'H>H/(K]%/@]\7M/\
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M)FB$$PF0E'C92&4CJ".H-?7O[%?PDU:UUK4O$][:O!%+!]EME<8+@L"[X].
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M!I5.57MKHC^:>(\PQM'.*\*6(G%)[*4K?=?0^J%OW_Z&75/^_P"/\*>+QO\
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M,SENM1O<1QR(KR(C.<(K, 6/MZT#;MJR>BF=Z-WK0,?13 WUI,\^] $E%,-
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ML(Q/<[=H)]J^ED<,H(YKX3$4YX>HX/H?3TJD:L;H^;9/V(/!\GWI;S_OXO\
MA563]@_P5+UFOA])%_\ B:^GJ*R5::V9KR1?0^5Y/^"?W@:3K<:C^$J?_$U5
MD_X)W> 9.MSJ?_?U/_B:^LJ*M8FLMI$^RAV/D23_ ()O?#R3K<ZI_P!_D_\
MB*JR?\$S?AQ)UNM6_P"_Z?\ Q%?8M%:+&XA;39/L*7\I\8R?\$O?AG)UN]9'
MTN(__B*Z'X:?\$]O 7PK\7Q>(M(GU*2^2&2WVW4RM&5?&<@*.>/6OJVBG+'8
MF<7"4VTQ1P]*+YE'4SM#T>/1;)+>,?*HQ6@6 R<T,V,U@Z]KB6,+ -S7+3IR
MJ2Y8FE2HJ:YI'G'[3OQH/P;^$OB#Q%:JLM_;0[+5'^[YSD)&2.X!;)'?%?F#
MX5^*27MUJ6H>(9CJVJ7P:2:[O/WDDC_4]O0=!7W!^U5X?F^)_P ,M:T6.7RY
M)T#PNW02(P9<^V1^M?F?#X<U/3=2DL+NQG@OH6V/"RG(/MZCW%?H&4T5AE;J
MSYFM76(;9]4_LD_%J[;XI?\ "'O(TFC:I%(]K"S$BWF0;L)Z*PW9'3(!K]%O
M"WAQ;=$=P,]:_.K]B7X/:C_PLJ#QAJMNUIINFQ2"W\P8,LKC;D#T5<\^IK[#
M^)7[0VE^ K>>[N;R&RTVS7?/<2-A5 _F3V Y)KR,XQ7[WV-)W.S!X6/\62/H
M-8PJ[0.,5SGB70%O(68#)^E</^SO^T9X:_: \(C5]#GD!1S'+:W("S1D$X++
MDX##D?XUZXZ!U(/>OFXRJ8>IKHT>O.$*T+=#X _;<^)]_P##'P_I.A:7/)9W
MVMS.)+F)BLD<" ;@I'0L6 R.V:^7[/Q]I*^#_L@MH?M*MD,JC>#_ 'L]<^]?
M7/\ P4<^">I>-/#ND>(=%MWNKS1))&DMHUR\L#@;MH[E2H..XS7Y\:/HU[>$
MK#;2L_0KL((^OI7Z+EF)C6I7Z]3YJIAU0=C]-/V _C[J7Q(\%ZIX>UZX>\U#
MP_-'%!=RDEY;9U)C#GNRE67/4@#-?72,'4$=*_/K]B/P7??#_2-3U.]7RKK5
M)$;RNACC0$*#[G+'\:^X_#NO)>0J"W-?(YIA%&K*I3V9ZF#Q2E^[;.DHI <@
M$=*6OGSV!*^3/VVH]NM^%9!WMYU_)E-?6=?*'[;@_P")EX3/;RKCG\4KZKA=
MVS6E\_R9\%QTKY!B/^W?_2D'P)^(5Q\-?@A=ZO!H-UKT?]L/'+%:-AHE,:G>
M?E/&>.G>O,OBM\6M<^.>N6<$6F21VUJ2MKIMJK3/N;@LQ Y;H.@ KWS]C-BW
MPWU-".%U)_QRB&O>(;&W@<O%!%$YZLB &O8Q&:4,KS2O5=#GJ*3M*[TNNQ\Q
M@LAQ>>Y#A*,<6Z=%Q5XJ*=[/OH_T/&?V9?@_>_#?1+S4=900ZSJ87=;YR;>)
M<E5)_O$DD^G3M7E'[:S9\=:".@&FM^LAK[#QCFOCC]M1C_PGVC#/ TP_^C&K
M#(,55QV>+$5OB:?Y'9Q9E]#*>%I8+#*T8N*\W[UVWZL[_P -_#WQS\2_ NAK
M?^*&\)Z&EC$EK8:2"TTJ!  \TF1U'.T<#->-^*IO%_[./Q$%K:^(+B]146Y3
M?(QCN8B2-KHQ(SP1^H-?8GPO4K\-_"^1@_V;!_Z+%?*_[9OS?$NP'_4+7_T-
MZ[,CQ<L5F-3!5(Q=*7-I9=/Q^]L\OB;+X8'(Z69T9R5>/)[W,^MM+7LEY)'U
MYINNP7WANVUASY-O-:K=L6_@4IN/Y"OG/1_B=KO[17Q*?0M*U"\\.>$+:-II
MI+!MES.@( +/_#N)' Z#UKWCP+:PW_PUT&VN(Q-!-I<,<D;=&4Q $'ZBO,=<
M^,_A;X;ZE'X.\">'X]7ULR?9UL]/58H$D_NL^/F([XZ8Y(KYW+X*-2O3HT>>
MIJHO2T%UD[Z?>?9YM4<J&%JXG$*G1=G-*_-4;2M%6UL];I:L\Y_:,^'D7PEC
MT/6?#6L:Q;2W,[PR^9J$DC;@NX."3D'J#^%>]? ?QG>>.OA=I&IZC()K_P#>
M032 8WLC%=Q'J0 37@7[3>F^,(_#&A:CXLU:UDFN+MECTG3X=MO:_(3]\_,[
M=LGCTKUO]DT@?!NR]?M4^?\ ONO9S""J9%2K5)*<U-KF\M=+]3YK)ZCH\5U\
M/1@Z=.5-/D??W=;:I/\ IGA7[2'CWQ[>ZH?#OB2UBT336_?0VEF^Y+A Q"NS
MY^;ITXP>U'B?P]\4?%?A+POK5C;7S:&EK%#86.ERMYD(50HE=5P<N1D'G QT
MK;_;6 _X2_PX>_V"0?\ D2OHOX,L6^$_A(G_ *!L/_H(KOJX^.!RO!XFE1C=
MMZ6T[/YON>11RF6:Y_F& Q&)G91C9IZ[II;;*^RMW,>\T?X@W7PGT>UTS5[?
M3O&"01F[FND#B0[3N3." V2/FP>0:^4O!?BKQKKWQETB26\.L>)+>>6W@74I
MCY,;['5C@< #DX YQBOOC;7PM\'R&_:6M&'3^U;S'Y2UPY!653#8V4Z<7:+:
MT[WTOO;R/4XOPLJ&(RV,*LU><8/WG9VM9VVYO.QZ[XN_9M\6>*+>;4;SXAWE
M]K>TNL+(T5MNZ[5"M\H[=*\X^#OQN\=Z;J$WA* '7[ZZ+6]BFH2Y^RS X+,Y
MY*  DCVXK[2/7/>OA#X,_OOVC-/*?(/[3NFQ[?O.*UR?$RS#!XFGBHQDJ<>:
M.B5GKVMV,N(\%')\PP5; 5)0E5GR2]YNZ=N[>NIZ]XL_9L\9>(M,GU*^^(%Y
MJ.OJAD6WPT=MNZ[$PWRCL.*YO]E[XR:XWC*/PEK5[-J%G=(XMFN7+R02H"2N
MX\D$ \'ICBOK7AFZ5\(_!:/R_P!HO34 QMU*Z!'IA9:C+:[S3 8NEBDGR1YH
MZ)6WVLO(O/<)'(<TR_$8"4DZD^6=Y-\R;6]V]=6?6WQ@^*5I\)_";ZK<0_:K
MJ5O(M+8' DE()&3V4 $GZ5Y=\+/"NJ_';0)O$_C77-5\BYF>.TTS3[AK2W2-
M3C< O+9.<$GMWKV7QWIWA>;24U/Q7;64NGZ63<++?*&2)L8S@]2<XQ@YS7EV
MC_&S7/BEJL^C_#?1H;2PM<";6]57$4*GILA7J3S@$_4"O#P7-]3E]6IVDG[U
M1NRBNR[7\M3ZK-.19C#Z[6YJ;5H48IMREUDTMTNE_=6[9XFWB'5_@C\<;C2-
M-U>]ETB'4(XI+>YG,BRP/M.&!/W@&Z]>*^W;J\BL[66YGD6&WB0R22-P%4#)
M)_"OS_\ BQIMYI7QFOK;4=2DU>]2\M_-O9(UC,A(0_=7@ 9P .PKZ^_: ENH
M?@MXG-F3YGV0*Q!Y"%E#_P#CN:]O/L-&L\"TUS5(I.7?;7\3Y?A3&U,+_:D6
MGR49-QBW>WQ.RW[=#R)?B?XI_:%^(,GA_P ,:G+X:\+VZF2>[M^+B2($#=N[
M%B>%'3J<UH?&3]G]?#?@R?7?"NHZ]+J]B5EF62_EE::/^)@,\,/O<>AKE/V+
MM5MK;QAKUA(56XNK-'BSU8(YW ?]]#\J^O\ ''-8YKB)Y+F"P^%C:$+:?S=^
M;O<ZN'\'3XFRF>+Q\G*K5<E>_P %G9**Z6W\^IX1^R=XZ\0^,_#.J1:W--?0
MV$R1VU]."7<$'<A8_>*X'/7YJX[X@?&C5?B5\2(/!/AK6/\ A'=$%PT%UJR.
M$>3;GS&#$_*HP0 #R?:OIC4X3;Z+?+9QB.3R)#&L:A?FVG'XYKX$^!^F:-K7
MQ2T;3O$=I'>V%VTD+PW&=K2%3MS[[OU-;Y73PV.J8O,734>17C%).SL];.R;
MTOZG'GU7&Y1ALOR95W)U)6E-MIM76EU=I.]KK6R/>O&GP=\/:'X7O-2\+>-K
M^U\064+3I,^M%_M!49*D;N"<'&WOVK8_9E^-U]\1(;K0]><3:Q9Q":*ZP%-Q
M%D [@/XE)'US79?\,[?#;:/^*.TT$>B,/ZUL^&?A/X0\&ZG_ &CHFA6VFWNP
MQ^?%NSM/4<D^@KQZN8X6MA)T*W-.>\9-)->5[MV\CZ/#Y+F&&S&EBL/R4J:T
MG",I-27>SBDFN_4^;/VC['7/A;K6FOI7C/Q#+#J8FF:.XOG/E$,.%QCCYNGM
M7T%\')+GQ#\&O#[WE]<2W5WI^)+SS"9LMD;MQYW#U]J\-_;8).L>% >GD3\?
M\"6O<_@+M'P=\);>GV%.GKSFN_,K2R/"UFES.3ULNESRLG_=\58W#1;Y%!:7
M;6O+>U_4^;/V@K?7OA+XBT[3]+\:>);JWNK0S,UYJ#,P8,5X*XX_"OISP,M]
MKWPBT3_B930:C=Z5%_Q,.'D21HQ^\^;J<\\U\X?MJ2[O'FAIG[NFDX^LC?X5
M],?"/_DE_A3_ +!EO_Z *,UURC!UFES-N[LM?4G(5R\29AA8R?LXQ5E=V5[7
MMKH?$'QB\*W'A;XGWVD7>KW6MW.86?4+O_6/O /3/;-?6?@'X.ZSX1U1K^X\
M?:UK"26CPI;79RD;,!AP"QY7'%?-G[2D@?X]:F!_"UJI_P"^$K[GM\?9XO\
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M&)6 %I&(P7D8[F8_4DU]#Z!XN2955VY^M>97.D-8,%5?+*\ @5Y%\>/V@?\
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MPPW-B)1G0^&22\K75K:61\P_$KP5\0OC?X3GU;4=)30!IP\S3/#X8//<,?\
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 A4-4<=K#$TCI$B-(=SLJ@%CZGUJ6B@5D(% I:**!A1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!#-"D\;(X!!XKQWXB?#6]
MTNUU75- MY+SS8G:?3(AEI"5(WQC^_TR._UKV;;1M]ZZL-B)X6HJD/\ ASRL
MSRW#YMAI8;$K1]>J?='S-^S1^RG#X'^R>*_&,$=YXH=1);V+8:+3<_HTOJW1
M>@]:^FMH]*-M+1B<35Q=1U:SNV:X' T,NH*AAXVBOQ\WYA1117*>@%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
